TY  - JOUR
AU  - Blanco-Ruiz, Marina
AU  - Amaya-Pascasio, Laura
AU  - de Torres Chacon, Reyes
AU  - Josefa Alvarez Soria, Maria
AU  - Arjona-Padillo, Antonio
AU  - Carrillo Bailen, Maria Magdalena
AU  - Milan Pinilla, Rodrigo
AU  - Perez Ortega, Irene
AU  - Sanchez Rodriguez, Belen
AU  - Andrade Zumarraga, Luis
AU  - Valverde Moyano, Roberto
AU  - Payan Ortiz, Manuel
AU  - Castillo Fernandez, Alba Maria
AU  - Del Toro Perez, Cristina
AU  - Gonzalez Bustos, Pablo
AU  - Aguera Morales, Eduardo
AU  - Sanchez Lopez, Purificacion
AU  - Hidalgo Martin, Beatriz
AU  - Roa Chamorro, Ricardo
AU  - Fernandez Perez, Javier
AU  - Mejias Olmedo, Maria Victoria
AU  - Martinez-Sanchez, Patricia
PY  - 2021
DO  - 10.1016/j.athplu.2021.08.009
UR  - https://hdl.handle.net/10668/24985
T2  - Atherosclerosis plus
AB  - Background and aims: The benefits of the PCSK9 inhibitors, alirocumab and evolocumab, in lowering LDL-cholesterol and preventing major adverse cardiac events (MACE) have been demonstrated in pivotal clinical trials. However, few studies of routine...
LA  - en
PB  - Elsevier
KW  - Evolocumab
KW  - Alirocumab
KW  - PCSK9i
KW  - Hypercholesterolemia familiar
KW  - Cardiovascular disease
KW  - Statins intolerance
KW  - Heterozygous familial hypercholesterolemia
KW  - Statin therapy
KW  - Double-blind
KW  - Evolocumab
KW  - Management
KW  - Ezetimibe
KW  - Trial
TI  - Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
TY  - research article
VL  - 45
ER  -